characteristics.text: 2012-11-06T17:02:05Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2018-03-08T16:06:54Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA1573457
characteristics.characteristic: External Id
characteristics.text: Geuvadis
characteristics.characteristic: INSDC center name
characteristics.text: 2012-11-06T17:02:05Z
characteristics.characteristic: INSDC first public
characteristics.text: 2018-03-08T16:06:54Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS185220
characteristics.characteristic: SRA accession
characteristics.text: GEUV:NA18867
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0009737
characteristics.characteristic: broker name
characteristics.text: human
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: common name
characteristics.text: Protocols: For more information about the populations, ELSI, etc., see http://www.1000genomes.org/about#ProjectSamples and http://ccr.coriell.org/Default.aspx. EVB transformed lymphoblastoid cell lines (LCLs) from Coriell Cell Repositories (GBR, FIN, TSI) and University of Geneva (CEU, YRI) were shipped to ECACC (European COllection of Cell Cultures) as live cultures (06/2011 - 09/2011), in batches of ~ 30 samples from Coriell (GBR/FIN/TSI more or less randomized) and 2 x ~90 samples (by population) from Geneva. In ECACC, these cell lines were cultures to approximately 1.2 x 10e8 cells (06/2011-10/2011). These cultures were split to produce 8 x cell banks of the samples, and a snap frozen pellet of 2 x 10e7 cells from a proliferating culture. The cell pellets were shipped from ECACC to University of Geneva in three batches, the first batch consisting of CEU/GBR/FIN/TSI samples, and the second and third batch with YRI and some CEU samples. Total RNA was extracted from cell pellets using the TRIzol Reagent (Ambion). The pellets had been frozen at ECACC without any additives like RNAlater or Trizol. In Geneva they were thawed, 1mL of trizol was added in each sample, and the samples were transferred to eppendorf tubes. The rest of the protocol followed the manufacturer's guidelines. No DNAse treatment was done to the RNA samples. The RNA quality was assessed by Agilent Bioanalyzer RNA 6000 Nano Kit according to the manufacturer's instructions. The sample information includes a visual inspection of RNA quality (degradation), in the scale 0, 0.5, 1. RNA quantity was measured by Qubit 2.0 (Invitrogen) using the RNA Broad range kit according to the manufacturer's instructions.
characteristics.characteristic: description
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: YRI
characteristics.characteristic: population
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: lymphoblastoid cell line
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0005292
characteristics.characteristic: strain
characteristics.text: NA18867
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/CL_0000895
characteristics.characteristic: title